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In vitro and in vivo studies have demonstrated that UCB (uncon-
jugated bilirubin) is neurotoxic. Although previous studies sug-
gested that both MRP1 (multidrug resistance-associated protein
1) and MDR1 (multidrug resistance protein 1) may protect cells
against accumulation of UCB, direct comparison of their role in
UCB transport was never performed. To this end, we used an indu-
cible siRNA (small interfering RNA) expression system to silence
the expression of MRP1 and MDR1 in human neuroblastoma
SH-SY5Y cells. The effects of in vitro exposure to clinically-
relevant levels of unbound UCB were compared between
unsilenced (control) cells and cells with similar reductions in the
expression of MRP1 or MDR1, documented by RT–PCR (reverse
transcription–PCR) (mRNA), immunoblotting (protein), and for
MDR1, the enhanced net uptake of a specific fluorescent substrate.
Cytotoxicity was assessed by the MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide] test. MRP1-deficient
cells accumulated significantly more UCB and suffered greater
cytotoxicity than controls. By contrast, MDR1-deficient cells
exhibited UCB uptake and cytotoxicity comparable with controls.
At intermediate levels of silencing, the increased susceptibility to
UCB toxicity closely correlated with the decrease in the expres-
sion of MRP1, but not of MDR1. These data support the concept
that limitation of cellular UCB accumulation, due to UCB export
mediated by MRP1, but not MDR1, plays an important role in
preventing bilirubin encephalopathy in the newborn.
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INTRODUCTION
In humans and rodents, UCB (unconjugated bilirubin) may be
neurotoxic. In some neonates with severe hyperbilirubinaemia,
UCB accumulates in neurons and astroglial cells in specific
brain regions, causing encephalopathy and kernicterus [1]. Initial
in vitro studies of the effects of UCB on mouse neuroblastoma cell
lines revealed a higher sensitivity to UCB toxicity of mitotically
active N2AB-1 cells than of ‘mature’ neurons [2], and a progres-
sive and irreversible toxicity in N-115 cells exposed to UCB for
one or more hours [3].
Toxic effects of UCB are greatly decreased by tight binding to
plasma albumin, since only the unbound diacid species of UCB,
which is dominant at physiological pH [4,5], can diffuse rapidly
across cell membranes [6]. In vitro exposure of neurons or
astrocytes to UCB has shown neuroprotection at low, physio-
logical concentrations of Bf (unbound UCB), but neuro-
toxicity at modestly higher Bf values [5,7]. Others reported
that UCB activated the mitochondrial pathway of apoptosis in
rat brain neurons, inducing mitochondrial depolarization and
Bax translocation via physical interaction with membranes [8].
Studies performed on human NT2-N neurons showed that UCB
induces rapid necrosis at high and moderate concentrations and
delayed apoptosis at low and moderate concentrations [9]. In
human neuroblastoma SH-SY5Y cells, clinically relevant UCB
concentrations cause early disruption of the mitochondrial
membrane potential and subsequently induce apoptosis [10].
Collectively these findings indicate that intracellular accu-
mulation of UCB may cause serious damage to nerve cells. This
prompted us to explore the mechanisms that may limit toxic
intracellular accumulation of UCB. The multidrug resistance-
associated protein, MRP1 (ABCC1), and the multidrug resistance
protein, MDR1 (P-Glycoprotein, ABCB1), belong to the
superfamily of the ABC (ATP-binding cassette) transporters [11].
MRP1 transports amphipathic anionic, glucuronide and sulphate
conjugates of steroid hormones and bile salts. In the presence
of physiological concentrations of reduced glutathione, MRP1
also transports unconjugated xenobiotics and uncharged drugs
[11–13]. MDR1 transports hydrophobic, either uncharged or
weakly positively charged compounds in their unmodified forms
and, in particular conditions, even highly charged, anionic
compounds [11]. Both MRP1 and MDR1 protect nerve cells from
toxic substances by promoting their active export from the cells
[14–18].
Studies using various experimental models demonstrated that
MRP1 is directly involved in the transport of UCB [19–21].
In plasma membrane vesicles from MDCKII cells (Madin-
Darby canine kidney II cells), the stable expression of human
MRP1 significantly increased the export of UCB with high
affinity, Km = 10 +− 3 nM (Bf) [22]. In cultured mouse astrocytes
and primary cultures of rat neurons and astrocytes, functional
inhibition of Mrp1 with MK571 engendered an increase in UCB-
induced toxicity [15], even at a normally non-toxic Bf of 40 nM
[23]. Collectively, these findings show that MRP1 exports UCB at
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relatively low, physiologically relevant Bf, and thus may protect
the cell from accumulation of toxic levels of UCB.
Other studies have suggested that Mdr1/MDR1 might also
transport UCB. UCB may be a weak substrate for Mdr1a [24]
and competitively inhibits the labelling of brain capillary MDR1
with a photoaffinity substrate [25]. A greater proportion of UCB
administered intravenously is taken up by the brains of mdr1a
(−/−) knockout mice compared with their mdr1a (+/+) controls
[26]. Although these studies suggest that MDR1 may be involved
in the transport of UCB, they were all performed with high doses
of UCB that yielded bilirubin concentrations vastly higher than
clinically relevant levels [27,28]. However, drugs known to inhibit
MDR1 function may increase the risk of bilirubin encephalopathy
in jaundiced neonates [29].
The aim of the present work was to directly compare the
role of MRP1 and MDR1 in the prevention of UCB-related
cytotoxicity in the human neuroblastoma SH-SY5Y cell line,
which expresses both proteins [30,31] and is highly susceptible
to UCB toxicity [10]. The expression of either MRP1 or MDR1
in these cells was modulated by using siRNAs (small interfering
RNAs) produced by an inducible vector, and net accumulation
and cytotoxicity of UCB were assessed. Our experiments are
the first to compare directly the protective role of MRP1 and
MDR1 against UCB toxicity in a single cell line under identical
experimental conditions. We demonstrate that knockdown of
MRP1, but not MDR1: a) decreases the cellular export of UCB
and increases the cytotoxicity of UCB over a range of clinically
relevant Bf levels (40–140 nM); and b) renders the cells sensitive
to UCB toxicity at low Bf levels that are non-toxic to control cells.
EXPERIMENTAL
Chemicals
DMEM (Dulbecco’s modified Eagle’s medium), L-glutamine,
penicillin streptomycin and trypsin (0.05%)/EDTA (0.02%)
in PBS without Phenol Red, Ca2+/Mg2+ were purchased from
Euroclone (Pero, Milano, Italy). Fetal bovine serum tetracycline-
free (Tet System Approved FBS, US-Sourced) was purchased
from Clontech. MEM (modified Eagle’s medium), non-essential
amino acids, MEM vitamin solution, Opti-MEM I reduced
serum medium and LipofectamineTM 2000 were purchased from
Invitrogen. Blasticidin S hydrochloride, puromycin dihydrochlor-
ide, doxycycline hyclate, PBS (Dulbecco’s Phosphate Buffered
Saline) without Ca2+/Mg2+, TRI REAGENTTM, bicinchoninc acid
protein assay kit, Ponceau S-solution (0.1% w/v) in 5% acetic
acid (v/v), MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide], DMSO and Hoechst 33342 were purchased
from Sigma. CPRG (chlorophenol red-β-D-galactopyranoside)
was purchased from Boehringer Mannheim (Indianapolis, IN,
U.S.A.). iScriptTM cDNA Synthesis Kit and iQTM SYBR Green
Supermix were purchased from Bio-Rad Laboratories. Cell lysis
buffer was purchased from Cell Signaling. ECL® (enhanced
chemiluminescence)-plus Western blotting detection system solu-
tions were purchased from Amersham-Pharmacia Biotech. UCB
was purchased from Sigma (St. Louis, MO, U.S.A.) and purified
as described by McDonagh and Assisi [32]. [3H]-Bilirubin (29.25
mCi/mmol) was biosynthetically labelled in vivo and then highly
purified from the bilirubin conjugates in bile as described [33].
Liquid-scintillation cocktail for radioassay (Filter counter N◦
6013149) was purchased from Packard Bioscience. MRP1-A23
rabbit antibody was prepared at our laboratory, as described in
[34]; anti-mouse IgG (Fc specific)-peroxidase antibody produced
in goat affinity isolated antibody, rabbit anti-actin affinity
isolated antibody and peroxidase conjugated-goat anti-rabbit
IgG-whole molecule affinity isolated antigen specific antibody
were purchased from Sigma. Anti-C219 (MDR1) monoclonal
antibody was purchased from Signet Laboratories (Dedham, MA,
U.S.A.).
Construction of pSUPERIOR-MRP1 and pSUPERIOR-MDR1 clones
We used pSUPERIOR.puro vector (Oligoengine, Seattle, WA,
U.S.A.), a tetracycline (or doxycycline)-regulated vector, for
inducible siRNA expression. The siRNA sequence against MDR1
was obtained by Wu et al. [35], whereas that against MRP1
was the silencer validated MRP1-siRNA (#51321-1651; Ambion,
Austin, TX, U.S.A.). The pSUPERIOR.puro vector was digested
by BglII and HindIII and the annealed oligonucleotides were
ligated and cloned into the vector. The constructs were confirmed
by sequencing. SH-SY5Y cells were transfected (Lipofectamine
2000) with the pcDNA6/TR vector (Invitrogen) expressing high
levels of the TetR (tetracycline repressor) gene and cells were
grown in medium containing 5 μg/ml blasticidin. After transient
transfection of the pcDNA4/TO/lacZ vector (Invitrogen), single
colonies were isolated and expanded. They were screened
for expression of the highest levels of tetracycline repressor
from pcDNA6/TR by assaying β-galactosidase expression upon
induction with 3.9 μM doxycycline, used as an alternative
inducing agent to tetracycline (half-life: 48 compared with
24 h, respectively), according to the pSUPERIOR manufacturer’s
suggestions. The clone showing the highest ratio of β-
galactosidase activity between induced and non-induced samples
was selected for transfecting the pSUPERIOR vector containing
the siRNA-expressing sequence targeting MRP1 or MDR1.
The empty pSUPERIOR.puro vector was also transfected and
used as control. Puromycin (0.8 μg/ml)-resistant colonies were
expanded for two additional months. The clones showing the
highest knockdown of MRP1 (pSUPERIOR-MRP1) or MDR1
(pSUPERIOR-MDR1) upon induction with 3.9 μM doxycycline
were selected by gene, protein and functional analysis.
Cell culture
SH-SY5Y cells were kindly supplied from the Mario Negri
Institute for Pharmacological Research (Laboratory of Molecular
Pharmacology) in Milan, Italy. Stable SH-SY5Y clones constitu-
tively expressed the tetracycline repressor from pcDNA6/TR
vector and inducibly expressed the siRNAs from pSUPERIOR
vector containing the siRNA-expressing sequence targeting
MRP1 (pSUPERIOR-MRP1 clone) or MDR1 (pSUPERIOR-
MDR1 clone). The cells were grown in DMEM supple-
mented with 2 mM L-glutamine, 10% (v/v) tetracycline-free
fetal bovine serum, 1% (v/v) MEM non-essential amino acids,
1% (v/v) MEM vitamin solution and 1% (v/v) penicillin/strep-
tomycin (100 units/ml penicillin and 100 μg/ml streptomycin).
Blasticidin (5 μg/ml) and puromycin (0.8 μg/ml) were added
as selection antibiotics for pcDNA6/TR and pSUPERIOR.puro
respectively. Clones were maintained at 37 ◦C in humidified air
with 5% CO2. On the day prior to the experiment, confluent cells
were trypsinized and plated in either: 1) 35 mm plates at a density
of 2.5 × 106 cells/well for RT (reverse transcription)-real time
PCR and Western blot analyses; 2) in 12-well plates at a density of
1 × 106 cells/well for the [3H]UCB-uptake assay; or 3) in 96-well
plates at a density of 0.2 × 106 cells/well for MTT assay and for
Hoechst 33342 dye accumulation assay. Doxycycline (3.9 μM)
was used to induce the siRNA expression from pSUPERIOR.puro
vector. Before the harvest or treatments, clones were incubated
with and without doxycycline (induced and non-induced samples
respectively) at 37 ◦C for various time intervals.
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RNA isolation, reverse transcription and RT-real time PCR
The pSUPERIOR-MRP1 clone was incubated with doxycycline
(3.9 μM) for 24, 48 or 72 h, or for 48 h followed by an additional
48 h without doxycycline (induced samples). pSUPERIOR-
MDR1 was incubated with doxycycline (3.9 μM) for 24 or 48 h, or
for 24 h followed by additional 24 h without doxycycline (induced
samples). The control clone, stably transfected with pcDNA6/TR
vector and with an empty pSUPERIOR.puro vector, was treated
with doxycycline (3.9 μM) as described for pSUPERIOR-MRP1
and pSUPERIOR-MDR1 clones. For each induced sample, a non-
induced sample was tested. Total RNA was isolated from each
clone and from its control using TRI REAGENTTM, according
to the manufacturer’s recommendations. One μg of total RNA
from cell culture was reverse transcribed using the iScript cDNA
Synthesis Kit, according to manufacturer’s instructions, on a
thermal cycler (Gene Amp PCR System 2400, PerkinElmer,
Boston, MA, USA). The relative levels of MRP1 mRNA with
sense (GCCAAGAAGGAGGAGACC) and anti-sense (AG-
GAAGATGCTGAGGAAGG) primers and the MDR1 mRNA
with sense (TGCTCAGACAGGATGTGAGTTG) and anti-sense
(AATTACAGCAAGCCTGGAACC) primers were assayed by
RT-real time PCR using iQ SYBR Green Supermix, as described
previously [15]. Amplification, data acquisition and data analysis
were carried out using the iCycler IQ (Bio-Rad Laboratories,
Hercules, CA). Each sample was analysed in triplicate. For
each amplification, a blank (nuclease-free water) was added in
place of cDNA. The thermal cycler conditions were: 95 ◦C for
3 min, 40 cycles at 95 ◦C for 20 min, 60 ◦C for 20 min and 72 ◦C
for 30 min. In each reaction, a standard curve was generated
by serial dilution of isolated and quantified cDNA (chosen
among the cDNA samples) and a melting curve was generated
to verify the specificity of the amplification. The results were
normalized to each housekeeping gene and the initial amount
of the template of each sample was determined as relative
expression against the non-induced control sample chosen as
reference. β-ACTIN with sense (CGCCGCCAGCTCACCATG)
and anti-sense (CACGATGGAGGGGAAGACGG) primers and
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) with
sense (CCCATGTTCGTCATGGGTGT) and anti-sense (TGGT-
CATGAGTCCTTCCACGATA) primers were used as endogen-
ous controls to normalize the expression level of target genes.
Western blotting
pSUPERIOR-MRP1 clone was incubated with doxycycline
(3.9 μM) for 24, 48 or 72 h, or for 72 h followed by 72 h without
doxycycline (induced samples). pSUPERIOR-MDR1 clone was
incubated with doxycycline (3.9 μM) for 24 or 48 h, or for 48 h
followed by 48 h without doxycycline (induced samples). The
control clone, stably transfected with pcDNA6/TR vector and with
an empty pSUPERIOR.puro vector, was treated with doxycycline
as described for pSUPERIOR-MRP1 and pSUPERIOR-MDR1
clones. For each induced sample, a non-induced sample was
tested. Proteins of each sample were subjected to SDS/PAGE with
10% acrylamide and the resolved protein bands transferred onto
a nitrocellulose membrane (0.2 lm Protran BA 83, Schleicher
and Schuell, Dassel, Germany). Membranes were blocked for
1 h at room temperature (22 ◦C) in milk-TTBS [4% (w/v) non-
fat dried skimmed milk, 0.2% Tween 20, 20 mM Tris/HCl and
500 mM NaCl, pH 7.5] and then incubated overnight at 4 ◦C with
a 1:600 dilution of the MRP1-A23 rabbit antibody, 1:50 dilution
of the anti-C219 (MDR1) mouse antibody or 1:1500 dilution of
rabbit anti-actin antibody. After washing three times with milk-
TTBS, the membranes were incubated in blocking solution for
1 h at room temperature with secondary antibodies: peroxidase
conjugated-goat anti-rabbit (1:6000) or anti-mouse IgG (Fc
specific)-peroxidase (1:2000). Protein bands were detected by
ECL®-Plus, transferred to Kodak film and visualized by Kodak
EDAS 260 (Kodak Instruments, New Haven, CT, U.S.A.) using
Kodak 1D image software. The intensities of protein bands
were quantified by Scion Image (Frederick, MD, U.S.A.). To
quantify the relative expression of the proteins (MRP1/ACTIN
or MDR1/ACTIN), serial dilutions of a reference sample were
loaded on each gel, optical density was recorded and a standard
curve was generated from the serial dilutions by non-linear
regression analysis (Curver Expert 1.3 software, Starkville, MS,
U.S.A.). The correlation coefficient of the calibration curve was
never lower than 0.995.
[3H]-UCB uptake in cultured cells
pSUPERIOR-MRP1 clone was treated with UCB 72 h after
induction of the siRNA-expressing sequence transcription by
doxycycline (3.9 μM), and pSUPERIOR-MDR1 clone was
treated with UCB 48 h after removing the doxycycline from cells
previously incubated with doxycycline for 48 h. These incubation
conditions were predetermined to be the best for observing the
silencing of MRP1 and MDR1 respectively (see the Results
section). [3H]UCB (29.25 mCi/mmol) was dissolved in 0.3%
(v/v) DMSO and diluted in culture medium supplemented with
15% (v/v) fetal bovine serum containing 54 μM albumin. Cells
were incubated for 30 min in the presence of [3H]UCB (15 μM) at
Bf = 40 nM, determined as described previously [36]. The cells
were then carefully washed with ice-cold PBS to arrest UCB
uptake and remove loosely-bound [3H]UCB. The quantity of
[3H]UCB retained by cells, normalized for protein concentration,
was measured as previously described [19].
MTT assay and Hoechst 33342 dye accumulation assay
MTT assay is used for measuring the activity of enzymes that
reduce MTT to formazan. Yellow MTT is reduced to purple
formazan in the mitochondria of living cells by active mito-
chondrial reductase enzymes; therefore conversion is used as a
measure of viable cells.
pSUPERIOR-MRP1 and pSUPERIOR-MDR1 clones were
incubated with doxycycline (3.9 μM) for the same durations
selected to analyse protein content (see above). For each
induced sample, a non-induced sample was included, and each
treatment was performed in quadruplicate. After the appropriate
doxycycline incubation time, cells were treated for 4 h with three
different concentrations of UCB (15 μM, 20 μM or 30 μM).
UCB was dissolved in 0.3%, 0.4% or 0.6% (v/v) of DMSO
respectively, and diluted in 100 μl of complete medium supple-
mented with 15% fetal bovine serum containing 54 μM albumin.
Bf concentrations were 40 nM, 70 nM and 140 nM respectively,
measured as described previously [36]. For each induced and non-
induced sample treated with UCB, an induced and a non-induced
sample treated with the same volume of DMSO, but not UCB,
were included as controls. Induced and non-induced samples, not
treated with either UCB or DMSO, were tested also. MTT assay
was performed as described previously [37], with absorbance
measured at 562 nm, using a microtiter plate reader (Beckman
Coulter). MTT assay was also performed on pSUPERIOR-
MDR1 clone exposed to ceftriaxone, a cephalosporin antibiotic
transported by MDR1 but not MRP1 [29,38,39]. Cell viability,
assessed by MTT reduction ability, of induced and non-induced
samples treated with UCB plus DMSO, was expressed as a
percentage of the respective samples treated with DMSO alone.
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Figure 1 Time course of the relative gene and protein expression of MRP1/MRP1 and MDR1/MDR1 in SH-SY5Y clones
(A) Relative MRP1 mRNA expression in pSUPERIOR-MRP1 clone at 48 or 72 h after induction by doxycycline (3.9 μM) and 48 h after the removal of doxycycline from cells previously incubated
with doxycycline for 48 h (48/48 h). RT-real time PCR was performed by normalizing MRP1 expression values to housekeeping genes GAPDH and β-ACTIN. Each bar represents the mean +− S.D.
of three separate experiments. ∗P < 0.02 and §P < 0.03 for induced compared with non-induced samples. (B) Western Blot analysis of MRP1 and actin proteins in the same clones under the
same treatments as in (A), except doxycycline was removed after 72 h from cells previously incubated with doxycycline for 72 h (72/72 h). Bands were visualized by Kodak 1D image software and
quantified by Scion Image software. The relative expression values were obtained by the Curver Expert software as described in the Experimental section. Each bar represents the mean +− S.D. of three
separate experiments. #P < 0.03 and ∗P < 0.04 for induced compared with non-induced samples. (C) Relative MDR1 mRNA expression in pSUPERIOR-MDR1 clone at 24 or 48 h after induction
by doxycycline (3.9 μM) and 24 h after doxycycline removal from cells previously incubated with doxycycline for 24 h (24/24h). RT-real time PCR was performed by normalizing MDR1 expression
values to housekeeping genes GAPDH and β-ACTIN. Each bar represents the mean +− S.D. of three separate experiments. ∗P < 0.05 and §P < 0.02 for induced compared with non-induced samples.
(D) Western blot analysis of MDR1 and actin proteins in the same clones under the same treatments as in (C) except doxycycline was removed for 48 h from cells previously incubated with doxycycline
for 48 h (48/48 h). Band visualization and quantification is as in (B). Each bar represents the mean +− S.D. of three separate experiments. §P < 0.02 for induced compared with non-induced samples.
To assess MDR1 export function, accumulation of the Hoechst
33342 dye, a substrate for MDR1 [40], was measured in a
microtiter plate fluorescence reader (Beckman Coulter) at 350 nm
(excitation)/460 nm (emission), using 0.2 × 106 cells/well in 96
well black plates. After the appropriate incubation time with
doxycycline, cells were washed twice with Hanks solution and
exposed for 6 min to three different concentrations of Hoechst
33342 (1.0, 2.5 and 5.0 μM), dissolved in Hanks solution. Cellular
dye uptake was assessed by the increase in fluorescence. At the
end of each experiment, cell viability was assessed by the MTT
test, as described above.
Statistical analysis
Results are given as means +− S.D. of at least three separate
experiments. Statistical analysis was performed by Student’s t
test and a P value of less than 0.05 was considered statistically
significant.
RESULTS
Gene and protein expression changes according to the incubation
time with doxycycline
MRP1/MRP1 expression of pSUPERIOR-MRP1 clone
In the samples induced with doxycycline for 72 h, MRP1 mRNA
expression (Figure 1A) decreased by about 45% as compared
with the non-induced samples (P < 0.02); no decrease was
observed with a shorter incubation time (48 h). A 40% decrease
(P < 0.03) was also observed in samples incubated with doxycyc-
line for 48 h and then without doxycycline for an additional 48 h.
Protein analysis confirmed the variations observed in gene
expression. As shown in Figure 1(B), no change in the MRP1 level
was observed in both induced and non-induced samples after 48 h
of incubation with doxycycline. On the contrary, a 60% reduction
(P < 0.03) was found after 72 h of incubation. A similar decrease
in MRP1 content (approx. 50%) occurred in samples induced by
doxycycline for 72 h and then incubated without doxycycline for
an additional 72 h (P < 0.04). The control clone, stably transfected
with pcDNA6/TR vector and with an empty pSUPERIOR.puro
vector, showed a 10% upregulation of MRP1/MRP1 after 72 h of
incubation with doxycycline (results not shown).
MDR1/MDR1 expression of pSUPERIOR-MDR1 clone
After a 24 h incubation with doxycycline, the expression of MDR1
mRNA (Figure 1C) decreased by 30% (P < 0.05), but partially
recovered by 48 h. The reduction in gene expression was greater
than 50% (P < 0.02) when the clone was incubated for 24 h in
the presence of doxycycline followed by an additional 24 h in its
absence. The expression of MDR1 protein (Figure 1D) did not
show any decrease after 24 or 48 h of incubation with doxycycline,
but was reduced by approx. 60% (P < 0.02) 48 h after the removal
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Figure 2 3[H]UCB accumulation by MRP1- or MDR1-deficient SH-SY5Y
clones
Before exposure to 3[H]UCB, the induced samples of pSUPERIOR-MRP1 clone were incubated
with doxycycline (3.9 μM) for 72 h, whereas the induced samples of pSUPERIOR-MDR1 clone
were incubated with doxycycline (3.9 μM) for 48 h followed by an additional 48 h in medium
without doxycycline. At these incubation times, the levels of MRP1 and MDR1 proteins were com-
parably decreased (see Figures 1B and 1D). Both induced and non-induced samples were
incubated with 3[H]UCB at Bf = 40 nM for 30 min. The 3[H]UCB contents of the induced and
non-induced samples were measured and normalized for the respective cell protein content.
Results are reported as the means +− S.D. of experiments performed in triplicate. Induced
samples of pSUPERIOR-MRP1 clone accumulated 2.6-fold as much 3[H]UCB (#P < 0.0006) as
non-induced samples, whereas no difference was observed between induced and non-induced
samples of the pSUPERIOR-MDR1 clone.
of doxycycline from cells previously incubated with doxycycline
for 48 h. Taking into account the limited specificity of the anti-
C219 antibody, these results are compatible with the observation
that the silencing by siRNA was hidden by the induction of
MDR1/MDR1 expression caused by doxycycline, as previously
reported [41]. Doxycycline-related induction of 25% was also
observed in the control clone stably transfected with pcDNA6/TR
vector and with an empty pSUPERIOR.puro vector, after a 24 h
(for gene) or 48 h (for protein) incubation in the presence of
the antibiotic followed by a 24 h (for gene) or 48 h (for protein)
incubation in its absence (results not shown). This finding explains
why the silencing effect could be observed mainly only after
removing the doxycycline. The small reduction in the gene but
not in the protein expression observed after a 24 h incubation
with doxycycline (Figures 1C and 1D), as well as the different
incubation times needed to achieve maximum silencing in gene
or protein expression, is related to the shorter half life of mRNA
than the protein [42].
These findings defined the optimal incubation times to achieve
comparable decreases in the expression levels of MRP1 or MDR1
to correlate with UCB accumulation and cytotoxicity.
UCB accumulates in MRP1-deficient cells, not in
MDR1-deficient cells
Figure 2 shows the effects of decreased expression of MRP1 or
MDR1 on the intracellular accumulation of UCB after incubation
for 30 min with [3H]UCB (Bf = 40 nM). Accumulation of
[3H]UCB was markedly higher (2.6-fold) in the doxycycline-in-
duced samples of the pSUPERIOR-MRP1 than in the non-
induced ones (P < 0.0006). By contrast, the intracellular accu-
mulation of [3H]UCB was similar in the induced and non-induced
pSUPERIOR-MDR1. Since the decreased expression of both
proteins was comparable in the two clones (see Figures 1B and
1D), these results confirm that MRP1, but not MDR1, can regulate
the cellular content of UCB at the low Bf of 40 nM.
Figure 3 Cellular accumulation of a fluorescent MDR1 substrate by MDR1-
deficient SH-SY5Y clone
Before exposure to the fluorescent dye Hoechst 33342, the induced samples of
pSUPERIOR-MDR1 clone were treated with doxycycline as described in Figure 2. Cell content
of Hoechst 33342 was measured in 96-well, black microtiter plates by a fluorescence reader
at 350 nm (excitation)/460 nm (emission), using 0.2 × 106 cells/well. (A) Time-dependent
increase in cell fluorescence due to the uptake of 5 μM Hoechst in pSUPERIOR-MDR1 clone
induced () or non-induced (H17009) with doxycycline. (B) Cell fluorescence determined after 5 min
of incubation with three different concentrations of Hoechst dye (1, 2.5 or 5 μM). Results are
expressed as the means +− S.D. of three independent measurements. #P < 0.001 for induced
compared with non-induced samples. Dramatic increases in dye accumulation by induced cells
are observed at all dye concentrations.
Impairment of transport function and viability
in MDR1-deficient cells
As shown in Figure 3, compared with non-induced cells, induced
pSUPERIOR-MDR1 samples showed a dramatic increase in
the cellular accumulation of three different concentrations of the
fluorescent dye Hoechst 33324. These results demonstrate that
the knockdown of MDR1 expression resulted in functional impair-
ment of the export of the dye, a known substrate for MDR1 [40].
When the induced clone with its MDR1 level decreased by
60% was exposed for 24 h to 15 mM ceftriaxone, cell viability
was decreased by two-thirds compared with the non-induced
clone (35 +− 6% compared with 100 +− 4%, P < 0.002) (results
not shown). This confirmed that the decreased export function of
MDR1 in the induced cells engendered greater susceptibility to
cytotoxicity from a known MDR1 substrate.
UCB-induced cytotoxicity occurs in cells deficient in MRP1
but not MDR1
Figure 4 shows the cytotoxic effects of 4 h of exposure to
UCB at Bf = 40, 70 or 140 nM, on pSUPERIOR-MRP1 and
pSUPERIOR-MDR1 clones with comparable silencing of MRP1
and MDR1 respectively. Cell viability was assessed by the MTT
c© The Authors Journal compilation c© 2009 Biochemical Society
310 L. Corich and others
Figure 4 Cell viability of SH-SY5Y MRP1- or MDR1-deficient clones after
exposure to UCB
Before exposure to UCB, the induced samples of pSUPERIOR-MRP1 clone (A and C) and of
pSUPERIOR-MDR1 clone (B andC) were treated with DOX as described in Figure 2. Clones were
then exposed for 4 h to increasing concentrations of unbound UCB (Bf = 40, 70 or 140 nM),
and viability was then assessed by their ability to reduce MTT. Both induced and non-induced
samples were incubated in the presence of 0.3, 0.4 or 0.6 % (v/v) DMSO (used to dissolve the
UCB) and 15 % fetal bovine serum (albumin concentration 54 μM). Cell viability of induced
and non-induced clones is expressed as a percentage of the corresponding control (CTRL)
treated with DMSO only. Each bar represents the means +− S.D. of three separate experiments.
#P < 0.001 and ∗P < 0.0002 for induced compared with non-induced samples. §P < 0.02
for Bf = 40 nM compared with Bf = 70 nM and ∼P < 0.01 for Bf = 70 nM compared with
Bf = 140 nM.
assay. All pSUPERIOR-MRP1 samples, whether or not induced
with doxycycline for 72 h, showed progressive reduction in cell
viability by increasing Bf. However, the decrease in viability was
significantly greater in the induced cells with a 60% reduction
of MRP1 (see Figure 1B) at each Bf level (Figure 4A), and this
effect was UCB dose-dependent (Figure 4C).
In contrast to the pSUPERIOR-MRP1, no difference in
cytotoxicity was found between induced and non-induced samples
of the pSUPERIOR-MDR1 (Figures 4B and 4C), even at the
highest Bf (140 nM), although the induced clone reached a 60%
reduction of MDR1 expression by incubation with doxycycline
for 48 h followed by additional 48 h in its absence (see Figure 1D).
In spite of the substantial reduction in MDR1 expression, the sus-
ceptibility of the induced clone to UCB was comparable with that
Figure 5 Correlation between UCB-induced cytotoxicity and MPR1 protein
expression in SH-SY5Y clones
The pSUPERIOR-MRP1 clone was incubated with doxycycline as reported in Figure 1(B) and
UCB treatment was performed as described in Figure 4. At each Bf, there is a significant linear
correlation between the MRP1 protein content (normalized for actin) of induced cells relative to
non-induced (control) cells, and UCB cytotoxicity, expressed as cell viability assessed by MTT
assay. The slope of the correlation increases with increasing Bf., Bf = 40 nM;H17009, Bf = 70 nM;
, Bf = 140 nM.
of the non-induced clone, in keeping with the lack of difference in
UCB accumulation (Figure 2). This is in sharp contrast to the clear
increase, in induced pSUPERIOR-MDR1 cells, of accumulation
of Hoechst 33342 (Figure 3), and cytotoxicity of ceftriaxone, two
known MDR1 substrates, which confirmed the decreased export
function of MDR1 in the induced cells.
In summary, greater accumulation of UCB markedly affected
the cell viability of MRP1-deficient cells and this effect was
dose-dependent. On the other hand, the MDR1-deficient cells
showed UCB accumulation and cell viability identical to their
non-induced control, in spite of a demonstrated impairment in
transport activity of the protein for a known substrate (Figure 3).
Collectively these results strongly point to a role of MRP1 but not
of MDR1 in the protection from UCB-induced cytotoxicity. This
conclusion was further supported by the strong linear correlation
between the relative expression of MRP1 and the cytotoxic effect
of UCB at all Bf concentrations tested (Figure 5).
DISCUSSION
Previous studies have indicated that nerve cells are particularly
sensitive to UCB toxicity [2,3,7–10,27]. MRP1 and MDR1 have
each been proposed to protect cells against UCB toxicity by
limiting the intracellular accumulation of the pigment. We had
previously demonstrated that MRP1 transports UCB with high
affinity [22] and protects MEF (mouse embryonic fibroblast) cells
from UCB toxicity by exporting the pigment from the cells [19].
Both Gennuso et al. [23], using differentiated mouse astrocytes,
and, more recently, Falca˜o et al. [15] using mature rat astro-
cytes and neurons, have shown dramatic increases in UCB-
induced cytotoxicity (impaired MTT reduction) following
blockade of Mrp1 by MK571, an inhibitor of Mrp1 function
[43]. Gennuso et al. [23] showed further that MK571
increased vulnerability of astrocytes to UCB-induced membrane,
mitochondrial and nuclear damage, even at a normally non-
toxic Bf of 40 nM. Others have suggested that UCB is also a
substrate for MDR1 [26] and that this transporter may protect
neural cells from toxicity by limiting accumulation of UCB
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[25,26,29]. However, those studies were performed at vastly high
and clinically irrelevant concentrations of UCB.
The present study is the first to compare directly the functional
roles of MRP1 and MDR1 in protecting against UCB toxicity in
identical cells exposed to identical, increasing concentrations of
UCB at clinically relevant Bf levels. The comparable reduction we
obtained in the expression levels of MRP1 and MDR1, utilizing
RNA interference technology, also allowed a direct comparison
of their relative roles in the transport of UCB and in the protection
against UCB neurotoxicity in cells differing only in the reduced
expression of either transporter.
Our experiments demonstrated that, at clinically relevant Bf
levels, protection from UCB cytotoxicity was correlated with
the level of expression of MRP1 but not MDR1. No significant
UCB-induced impairment in cell viability was observed, even
when maximal MDR1 silencing was achieved and its impaired
transport function confirmed by the significantly greater cellular
accumulation, in the cells with induced siRNA expression, of
Hoechst 33342 dye, a substrate for MDR1 [40]. In contrast, the
cytotoxic effect caused by ceftriaxone, another known substrate
for MDR1 [29,38,39], was significantly greater in the induced
cells than in non-induced cells. These findings clearly indicate
that decreased expression and function of MDR1 is not associated
with greater UCB cytotoxicity at low Bf values.
The [3H]UCB uptake results confirm further the involvement
of MRP1 in UCB export, previously demonstrated by using
MEF cells isolated from Mrp1 knockout mice [19], and exclude
participation of MDR1 in the transport of UCB at low Bf
levels. They indicate also that the protective effects of MRP1
against UCB cytotoxicity are largely related to the ability of
this transporter to export UCB from the cell, thus limiting
intracellular accumulation of the pigment [19,20,22]. This is in
agreement with the chemical characteristics of the substrates
of the two proteins; MDR1 ‘prefers’ uncharged or slightly
positively-charged compounds, while MRP1 primarily transports
amphipathic, anionic conjugates, as well as unconjugated
xenobiotics and uncharged drugs [11–13]. Although our results
show no role for MDR1 in the transport of UCB at Bf = 40 nM,
they do not exclude the possibility, suggested by the work of
others [24–26,29], that MDR1 transports UCB at much higher
Bf levels. Many compounds are substrates for both high-affinity
(low Km) transporters that operate at low concentrations, and
low-affinity (high Km) transporters that are operative at much
higher concentrations of substrate [15,44,45]. In the case of UCB,
MRP1 clearly is the high-affinity transporter, whereas MDR1 may
become operative only at Bf levels that are far above clinically-
relevant concentrations.
Our MRP1-knockdown model validly mimics the increases
in mRNA and protein expression of Mrp1 [15,46], and the
decreased susceptibility to UCB toxicity [47], that occur during
maturation of rodent neurons and astrocytes. Similar changes in
the expression of MRP1 might explain the higher vulnerability
of premature infants to UCB-induced neurological dysfunction
during moderate to severe neonatal jaundice [48–50].
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